LTRN: Lantern Pharma Inc. Stock

by  •  • Comments Off on LTRN: Lantern Pharma Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 59.07
Enterprise Value ($M) 37.13
Book Value ($M) 40.91
Book Value / Share 3.80
Price / Book 1.44
NCAV ($M) 40.60
NCAV / Share 3.77
Price / NCAV 1.45

Profitability (mra)
Return on Invested Capital (ROIC) -0.39
Return on Assets (ROA) -0.29
Return on Equity (ROE) -0.30

Liquidity (mrq)
Quick Ratio 16.18
Current Ratio 16.18

Balance Sheet (mrq) ($M)
Current Assets 43.34
Assets 43.65
Liabilities 2.74
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -17.88
Net Income -15.96

Cash Flow Statement (mra) ($M)
Cash From Operations -14.35
Cash from Investing -0.93
Cash from Financing -0.50

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
03-01 13D/A Bios Equity Partners, LP 11.80 -13.83
02-14 13G/A ProPhase Labs, Inc. 5.80 -30.64

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-18 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2023-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO
2023-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU
2023-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-03 37,890 188,547 20.10
2024-05-02 20,175 28,318 71.24
2024-05-01 30,636 38,457 79.66
2024-04-30 17,442 31,264 55.79

(click for more detail)

Similar Companies
LQDA – Liquidia Corporation LSDI – Lucy Scientific Discovery Inc.
LSTA – Lisata Therapeutics, Inc. MBIO – Mustang Bio, Inc.
MBRX – Moleculin Biotech, Inc.


Financial data and stock pages provided by
Fintel.io